Drug intelligence / Profile preview

HTMC0658

Development stage: Phase 2
Lead developer: Shanghai Yidian Pharmaceutical Technology Development
Modality: Small Molecules
Administration: Oral

Overview

HTMC0658 is an investigational small molecule drug developed by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., currently in clinical development. Its primary indication appears to be **lupus nephritis**, based on available regulatory and research summaries. In addition, an ongoing clinical trial is assessing its efficacy and safety in **chronic rhinosinusitis**. The detailed mechanism of action, specific molecular targets, and pharmacology have not been disclosed in public literature or regulatory filings as of this time.

Beyond the preview

Go deeper on HTMC0658.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTMC0658.

Explore the full profile